Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Hi SK
I think they are in the process of listing under the ticker ACUT, which will be after consolidation (20:1), hence the $2 to $3's . Any figures/volume shown for ACUT are to test that everything is working prior to the listing. All IMHO.
It can't be far away - Will we hear of an equity raise, via a placing to the special people?? We need cash to to be a going concern!
BB
Very good article and getting the word out there to those suffering with MS. Agree bobsson, anyone with SPMS or their carers would be chasing up this new treatment - IMHO.
BB
https://www.bioworld.com/articles/516959-single-patient-data-suggest-tiziana-nose-a-better-way-with-cd3-in-ms?v=preview
'Tiziana Life Sciences Inc.’s intranasal, fully human anti-CD3 monoclonal antibody will need testing in 10 or 20 more patients to confirm the signal in secondary progressive multiple sclerosis (SPMS), but key opinion leaders on a conference call March 14 sounded optimistic as they checked out the prospect’s early efficacy.'
BB
As you say Dunk, a proper trial would have over 100 people involved. However, are they lying about the results from one sufferer?
In time this will have more people involved. 12 months time this could be sped through due to it’s great results. It could also be cancelled. Let’s wait and see. If you want out - sell. It’s 40% up on a week ago.
I’ll hang on and probably buy more.
BB
Attached is a new research note from Zacks SCR:
https://scr.zacks.com/news/news-details/2022/TLSA-KOL-Discussion-and-SPMS-6-Month-Results/default.aspx
BB
Thank you for the update MRK2020.
2 days trading above $1, can we make the 10 consecutive days requirement on the first attempt?
BB
It was an hour long.
BB
Looks that way SJ1
Recruiting status: Withdrawn
Info: Withdrawn: The study stopped early, before enrolling its first participant.
I guess Covid is yesterdays news. It was 12 months in the build up though!!
BB
Howard Weiner, MD, Director of the Multiple Sclerosis Program at BWH and Chairman of Tiziana’s Scientific Advisory Board, commented, “The potential for intranasally administered foralumab to suppress microglial activation is a novel and well-tolerated immunologic approach to potentially treat SPMS, a form of MS that currently has no effective treatment. We are extremely pleased with the tolerability of intranasal foralumab and with the positive clinical and PET imaging responses observed after completion of six months of dosing in the first patient. We look forward to treating additional patients to fill a major unmet need for the treatment of SPMS.”
Tanuja Chitnis, MD, Principal Investigator and Professor of Neurology at Harvard Medical School (HMS) and senior neurologist at BWH and Massachusetts General Hospital added, “New treatments for progressive MS are urgently needed. Intranasal foralumab could revolutionize treatment for this disabling form of disease.”
Tarun Singhal, MD, Director of PET Imaging Program in Neurologic Diseases, associate neurologist and nuclear medicine physician at BWH commented, “The longitudinal PET imaging results suggesting sustained reduction in microglial activation in the first SPMS patient treated with foralumab, are highly encouraging. We are very excited to further investigate the effects of foralumab in SPMS patients using additional quantitative PET approaches.”
About the Role of Microglial Activation in Neurodegenerative Diseases
Activation of microglia is a hallmark of brain inflammation. It is believed to play an important role in the pathway leading to neuronal cell death in several neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, prion diseases, multiple sclerosis and HIV-dementia. The chronic activation of microglia causes neuronal damage through the release of cytotoxic molecules such as pro-inflammatory cytokines, reactive oxygen intermediates, proteinases and complement proteins. Suppression of microglial inflammation has been considered as an important strategy in neurodegenerative disease therapy.
BB
'In addition to being well-tolerated, both biological and clinical improvements were seen in this patient using Tiziana’s novel immunotherapy technology, which, importantly overcame the challenge of delivering this antibody across the blood-brain barrier to affect immunomodulation in the brain.'
BB
Good post SJ1
Have we turned the corner, SP wise?
Would like to get a few more cheaply at the end of March, but happy to pay more if it's on it's way up.
BB
SJ1 is the man to help with that!
BB
Porky9: Well it’s looks like they went for it based on 25p. - What’s are they thinking ?
It is 0.25p (not 25p)
'nominal value 0.25 pence per ordinary share (the "Ordinary Shares")'.
BB
Bought more sub 26p - Bargain?????
BB
Tiziana Life Science (TLSA) did the same earlier last year, I believe, that was for $250m.
https://www.lse.co.uk/rns/TILS/tiziana-files-f-3-statement-with-us-sec-t5lp1kpa53j60hq.html
Haven't used it. Not sure if they can now as no longer ADR's - Full Nasdaq only listing.
BB
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_04122021_TLSA_Vandermosten.pdf
It seems so long ago now. They are talking about a valuation in 2027 just with Foralumab for MS & CD, I can wait. I also think that will be an underestimate, unless it includes major dilution.
BB
I'm good SK, just waiting for the $7.50 price target that was quoted last year to be hit!!!
BB
Original site - Acmsy = https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy = $0.13
Newly created - ACUT = https://www.cnbc.com/quotes/ACMSY?qsearchterm=acmsy = $2.50
New listing - Probably testing the site before listing on Nasdaq!
See new website: https://accustem.com/investors/
that states: Accustem Sciences Inc started trading on the OTC under ACUT on March 2, 2022. For more investor information please contact us using our contact form or emailing us at investors@accustem.com
BB
Well put Phil.
I like the cut of your Jib!
BB
Thanks Rockz. Let's hope we've turned a corner with TLSA.
BB